Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
Chun-Wei XuLu SiWen-Xian WangZiming LiZhengbo SongQian WangAijun LiuJinpu YuWenfeng FangWen-Zhao ZhongZhijie WangYong-Chang ZhangJingjing LiuShirong ZhangXiuyu CaiAnwen LiuWen LiPing ZhanHongbing LiuTangfeng LvLi-Yun MiaoLingfeng MinYu ChenJingping YuanFeng WangZhansheng JiangGen LinXingxiang PuRongbo LinWeifeng LiuChuangzhou RaoDongqing LvZongyang YuLei LeiXiaoyan LiChuanhao TangCheng-Zhi ZhouJunping ZhangJunli XueHui GuoQian ChuRui MengJingxun WuRui ZhangXiao HuJin ZhouZhengfei ZhuYongheng LiHong QiuFan XiaYuanyuan LuXiaofeng ChenRui GeEnyong DaiYu HanWeiwei PanJiancheng LuoHongtao JiaXiaowei DongFei PangKai WangLiping WangYoucai ZhuYanru XieXinqing LinJing CaiJia WeiFen LanHuijing FengLin WangYingying DuWang YaoXuefei ShiXiaomin NiuDongmei YuanYanwen YaoJianhui HuangYinbin ZhangPingli SunHong WangMingxiang YeDong WangZhaofeng WangBing WanDonglai LvQing WeiJin KangJiatao ZhangChao ZhangGenhua YuJuanjuan OuLin ShiZhongwu LiZhefeng LiuJing LiuNong YangLin WuHuijuan WangGu JinLiu YangGuansong WangMeiyu FangYong FangYuan LiXiaojia WangYiping ZhangShenglin MaBiyun WangXiaotian ZhangYong SongYuanzhi LuPublished in: Thoracic cancer (2022)
Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first "tumor agnostic" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription-polymerase chain reaction, and (DNA and/or RNA-based) next-generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first- and second-generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors.
Keyphrases
- squamous cell carcinoma
- lymph node metastasis
- papillary thyroid
- clinical practice
- copy number
- genome wide
- systematic review
- end stage renal disease
- genome wide identification
- newly diagnosed
- ejection fraction
- squamous cell
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- dna methylation
- genome wide analysis
- young adults
- tyrosine kinase
- protein kinase
- cancer therapy
- drug induced
- combination therapy
- loop mediated isothermal amplification